Alnylam Pharmaceuticals, Inc. (ALNY) News

Alnylam crossed a historic threshold in the first quarter of fiscal 2026 as robust global demand for its core transthyretin amyloidosis franchise drove record net product sales. The company achieved its first-ever quarter exceeding one billion dollars in product revenues while maintaining consecutive profitability.